JP2017537100A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537100A5 JP2017537100A5 JP2017528520A JP2017528520A JP2017537100A5 JP 2017537100 A5 JP2017537100 A5 JP 2017537100A5 JP 2017528520 A JP2017528520 A JP 2017528520A JP 2017528520 A JP2017528520 A JP 2017528520A JP 2017537100 A5 JP2017537100 A5 JP 2017537100A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- independently selected
- oxo
- carbocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 356
- -1 amino, hydroxyl Chemical group 0.000 claims description 330
- 125000000623 heterocyclic group Chemical group 0.000 claims description 256
- 125000004043 oxo group Chemical group O=* 0.000 claims description 214
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 206
- 150000001875 compounds Chemical class 0.000 claims description 160
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 131
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 106
- 125000001072 heteroaryl group Chemical group 0.000 claims description 102
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 86
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 82
- 125000000304 alkynyl group Chemical group 0.000 claims description 74
- 229910052739 hydrogen Inorganic materials 0.000 claims description 66
- 125000003118 aryl group Chemical group 0.000 claims description 64
- 125000003342 alkenyl group Chemical group 0.000 claims description 59
- 125000003545 alkoxy group Chemical group 0.000 claims description 58
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 56
- 239000001257 hydrogen Substances 0.000 claims description 54
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 54
- 125000001424 substituent group Chemical group 0.000 claims description 47
- 239000000203 mixture Substances 0.000 claims description 45
- 229910052757 nitrogen Inorganic materials 0.000 claims description 45
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 44
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 44
- 150000003839 salts Chemical class 0.000 claims description 42
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 36
- 206010028980 Neoplasm Diseases 0.000 claims description 32
- 125000005936 piperidyl group Chemical group 0.000 claims description 32
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 32
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 32
- 125000002837 carbocyclic group Chemical group 0.000 claims description 31
- 125000003566 oxetanyl group Chemical group 0.000 claims description 30
- 239000003112 inhibitor Substances 0.000 claims description 29
- 201000011510 cancer Diseases 0.000 claims description 26
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims description 24
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 20
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 20
- 229940127089 cytotoxic agent Drugs 0.000 claims description 20
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 18
- 239000002254 cytotoxic agent Substances 0.000 claims description 18
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 18
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 18
- 125000004076 pyridyl group Chemical group 0.000 claims description 18
- 229910052799 carbon Inorganic materials 0.000 claims description 17
- OTTXCOAOKOEENK-UHFFFAOYSA-N 2,2-difluoroethenone Chemical group FC(F)=C=O OTTXCOAOKOEENK-UHFFFAOYSA-N 0.000 claims description 16
- YWPMKTWUFVOFPL-UHFFFAOYSA-N 3,4-dihydro-2h-isoquinolin-1-one Chemical compound C1=CC=C2C(=O)NCCC2=C1 YWPMKTWUFVOFPL-UHFFFAOYSA-N 0.000 claims description 16
- 241001465754 Metazoa Species 0.000 claims description 16
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 16
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 16
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 claims description 16
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 16
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 16
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 16
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 claims description 16
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 16
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims description 16
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims description 16
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 15
- 125000006661 (C4-C6) heterocyclic group Chemical group 0.000 claims description 14
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 14
- 208000035475 disorder Diseases 0.000 claims description 14
- 230000003176 fibrotic effect Effects 0.000 claims description 14
- 206010039491 Sarcoma Diseases 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 230000001404 mediated effect Effects 0.000 claims description 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 10
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 10
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 claims description 10
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims description 8
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 8
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 8
- 206010016654 Fibrosis Diseases 0.000 claims description 8
- 208000019693 Lung disease Diseases 0.000 claims description 8
- PMDCZENCAXMSOU-UHFFFAOYSA-N N-ethylacetamide Chemical compound CCNC(C)=O PMDCZENCAXMSOU-UHFFFAOYSA-N 0.000 claims description 8
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 claims description 8
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 8
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 8
- 230000004761 fibrosis Effects 0.000 claims description 8
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 8
- 125000002971 oxazolyl group Chemical group 0.000 claims description 8
- 125000004351 phenylcyclohexyl group Chemical group C1(=CC=CC=C1)C1(CCCCC1)* 0.000 claims description 8
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 8
- 125000000335 thiazolyl group Chemical group 0.000 claims description 8
- 125000001425 triazolyl group Chemical group 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 201000009030 Carcinoma Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000003511 endothelial effect Effects 0.000 claims description 6
- 239000005556 hormone Substances 0.000 claims description 6
- 229940088597 hormone Drugs 0.000 claims description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 6
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 5
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 4
- 125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims description 4
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims description 4
- OFFFOVCCGHKJES-UHFFFAOYSA-N 4-methylthiadiazole Chemical compound CC1=CSN=N1 OFFFOVCCGHKJES-UHFFFAOYSA-N 0.000 claims description 4
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims description 4
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 4
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 4
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 4
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 claims description 4
- 201000004253 NUT midline carcinoma Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
- 229940123237 Taxane Drugs 0.000 claims description 4
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 4
- 206010057644 Testis cancer Diseases 0.000 claims description 4
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 claims description 4
- 208000009956 adenocarcinoma Diseases 0.000 claims description 4
- 125000005605 benzo group Chemical group 0.000 claims description 4
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 claims description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 229910052697 platinum Inorganic materials 0.000 claims description 4
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims description 4
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 claims description 4
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 4
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 4
- 201000003120 testicular cancer Diseases 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 claims description 3
- 239000005557 antagonist Substances 0.000 claims description 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 3
- 206010000830 Acute leukaemia Diseases 0.000 claims description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000026872 Addison Disease Diseases 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 229940125431 BRAF inhibitor Drugs 0.000 claims description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 2
- 201000009047 Chordoma Diseases 0.000 claims description 2
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000009798 Craniopharyngioma Diseases 0.000 claims description 2
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims description 2
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 claims description 2
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000011200 Kawasaki disease Diseases 0.000 claims description 2
- 208000002260 Keloid Diseases 0.000 claims description 2
- 102100034671 L-lactate dehydrogenase A chain Human genes 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- 108010088350 Lactate Dehydrogenase 5 Proteins 0.000 claims description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000007054 Medullary Carcinoma Diseases 0.000 claims description 2
- 208000000172 Medulloblastoma Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 101100523539 Mus musculus Raf1 gene Proteins 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 206010028594 Myocardial fibrosis Diseases 0.000 claims description 2
- 208000009525 Myocarditis Diseases 0.000 claims description 2
- 201000002481 Myositis Diseases 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 208000035327 Oestrogen receptor positive breast cancer Diseases 0.000 claims description 2
- 201000010133 Oligodendroglioma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 239000012828 PI3K inhibitor Substances 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 108091000080 Phosphotransferase Proteins 0.000 claims description 2
- 208000007641 Pinealoma Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 206010035742 Pneumonitis Diseases 0.000 claims description 2
- 208000008601 Polycythemia Diseases 0.000 claims description 2
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 206010036805 Progressive massive fibrosis Diseases 0.000 claims description 2
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 201000000582 Retinoblastoma Diseases 0.000 claims description 2
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims description 2
- 206010039705 Scleritis Diseases 0.000 claims description 2
- 201000010208 Seminoma Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 206010040070 Septic Shock Diseases 0.000 claims description 2
- 201000010001 Silicosis Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 208000001106 Takayasu Arteritis Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims description 2
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims description 2
- 206010044248 Toxic shock syndrome Diseases 0.000 claims description 2
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 206010053648 Vascular occlusion Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 208000014070 Vestibular schwannoma Diseases 0.000 claims description 2
- 206010047642 Vitiligo Diseases 0.000 claims description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 2
- 208000008383 Wilms tumor Diseases 0.000 claims description 2
- 230000001594 aberrant effect Effects 0.000 claims description 2
- 208000004064 acoustic neuroma Diseases 0.000 claims description 2
- 201000011186 acute T cell leukemia Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 230000000340 anti-metabolite Effects 0.000 claims description 2
- 229940044684 anti-microtubule agent Drugs 0.000 claims description 2
- 229940100197 antimetabolite Drugs 0.000 claims description 2
- 239000002256 antimetabolite Substances 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 230000006907 apoptotic process Effects 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 208000019748 bullous skin disease Diseases 0.000 claims description 2
- 230000022131 cell cycle Effects 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000024207 chronic leukemia Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 208000010932 epithelial neoplasm Diseases 0.000 claims description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical group C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 2
- 210000003743 erythrocyte Anatomy 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 230000001605 fetal effect Effects 0.000 claims description 2
- 201000003444 follicular lymphoma Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 210000004602 germ cell Anatomy 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 208000002409 gliosarcoma Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 208000025750 heavy chain disease Diseases 0.000 claims description 2
- 201000002222 hemangioblastoma Diseases 0.000 claims description 2
- 230000002440 hepatic effect Effects 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 210000003494 hepatocyte Anatomy 0.000 claims description 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims description 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 208000033065 inborn errors of immunity Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 210000001117 keloid Anatomy 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 206010024627 liposarcoma Diseases 0.000 claims description 2
- 230000001926 lymphatic effect Effects 0.000 claims description 2
- 208000003747 lymphoid leukemia Diseases 0.000 claims description 2
- 201000000564 macroglobulinemia Diseases 0.000 claims description 2
- 230000036210 malignancy Effects 0.000 claims description 2
- 210000001370 mediastinum Anatomy 0.000 claims description 2
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims description 2
- 206010027191 meningioma Diseases 0.000 claims description 2
- 230000004060 metabolic process Effects 0.000 claims description 2
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010028537 myelofibrosis Diseases 0.000 claims description 2
- 208000025113 myeloid leukemia Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 201000008026 nephroblastoma Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000004071 non-specific interstitial pneumonia Diseases 0.000 claims description 2
- 230000000414 obstructive effect Effects 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 125000003551 oxepanyl group Chemical group 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 208000004019 papillary adenocarcinoma Diseases 0.000 claims description 2
- 201000010198 papillary carcinoma Diseases 0.000 claims description 2
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims description 2
- 102000020233 phosphotransferase Human genes 0.000 claims description 2
- 208000024724 pineal body neoplasm Diseases 0.000 claims description 2
- 230000001817 pituitary effect Effects 0.000 claims description 2
- 201000006292 polyarteritis nodosa Diseases 0.000 claims description 2
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims description 2
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 239000003207 proteasome inhibitor Substances 0.000 claims description 2
- 150000003254 radicals Chemical class 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000002793 renal fibrosis Diseases 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 claims description 2
- 230000019491 signal transduction Effects 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 210000004243 sweat Anatomy 0.000 claims description 2
- 201000008753 synovium neoplasm Diseases 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 206010043207 temporal arteritis Diseases 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 206010043778 thyroiditis Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 208000021331 vascular occlusion disease Diseases 0.000 claims description 2
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical group CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003862 vemurafenib Drugs 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 99
- 125000006706 (C3-C6) carbocyclyl group Chemical group 0.000 claims 6
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 4
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 2
- 229940122558 EGFR antagonist Drugs 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 229940093499 ethyl acetate Drugs 0.000 claims 1
- 235000019439 ethyl acetate Nutrition 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 0 CC(N(C1)*c2c1c(Nc(cc1)ccc1-c1cccnc1C)n[n]2C)=O Chemical compound CC(N(C1)*c2c1c(Nc(cc1)ccc1-c1cccnc1C)n[n]2C)=O 0.000 description 104
- 125000005843 halogen group Chemical group 0.000 description 101
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- DGHJKOUXAHNRAP-UHFFFAOYSA-N 4-methyloxadiazole Chemical compound CC1=CON=N1 DGHJKOUXAHNRAP-UHFFFAOYSA-N 0.000 description 2
- LJPCNSSTRWGCMZ-YFKPBYRVSA-N C[C@@H]1COCC1 Chemical compound C[C@@H]1COCC1 LJPCNSSTRWGCMZ-YFKPBYRVSA-N 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- OSFVDNCNHWEOKC-GHRIWEEISA-N C/C(/c(cc1C(CC#N)C2)ccc1N2c1n[n](C2COCC2)c(CC2)c1CN2C(C)=O)=C\NC Chemical compound C/C(/c(cc1C(CC#N)C2)ccc1N2c1n[n](C2COCC2)c(CC2)c1CN2C(C)=O)=C\NC OSFVDNCNHWEOKC-GHRIWEEISA-N 0.000 description 1
- JMKKEJMTPPICOA-FWWKRHBFSA-N CC(/C=C(/c(cc1)cc2c1N(C)CCC2)\NC)=N Chemical compound CC(/C=C(/c(cc1)cc2c1N(C)CCC2)\NC)=N JMKKEJMTPPICOA-FWWKRHBFSA-N 0.000 description 1
- PRLAZICSKJHWGO-UHFFFAOYSA-N CC(C)CN(CC1)c(cc2)c1c(C)c2-c1c[n](C)nc1 Chemical compound CC(C)CN(CC1)c(cc2)c1c(C)c2-c1c[n](C)nc1 PRLAZICSKJHWGO-UHFFFAOYSA-N 0.000 description 1
- MASSWOMVPSTTLQ-WZQAJMDKSA-N CC(C)CN/C=C(\C=N)/c(cc1)ccc1Nc1n[n](C)c(CC2)c1CN2C(C)=O Chemical compound CC(C)CN/C=C(\C=N)/c(cc1)ccc1Nc1n[n](C)c(CC2)c1CN2C(C)=O MASSWOMVPSTTLQ-WZQAJMDKSA-N 0.000 description 1
- LYZIQOQONJWUCM-UHFFFAOYSA-N CC(C)Oc1ncccc1-c(cc1)ccc1Nc1n[n](C)c(CC2)c1CN2C(C)=O Chemical compound CC(C)Oc1ncccc1-c(cc1)ccc1Nc1n[n](C)c(CC2)c1CN2C(C)=O LYZIQOQONJWUCM-UHFFFAOYSA-N 0.000 description 1
- NCMLBFFUDRTDQF-UHFFFAOYSA-N CC(C1)CN(C)c2c1cc(-c1c[n](C)nc1)c(C#N)c2 Chemical compound CC(C1)CN(C)c2c1cc(-c1c[n](C)nc1)c(C#N)c2 NCMLBFFUDRTDQF-UHFFFAOYSA-N 0.000 description 1
- CIVLIHPKSFHIFY-UHFFFAOYSA-N CC(CN(CC1)CCC1[n](c(CC1)c2CN1C(C)=O)nc2N(CCCc1c2)c1cc(C(F)F)c2-c1c[n](C)nc1)(F)F Chemical compound CC(CN(CC1)CCC1[n](c(CC1)c2CN1C(C)=O)nc2N(CCCc1c2)c1cc(C(F)F)c2-c1c[n](C)nc1)(F)F CIVLIHPKSFHIFY-UHFFFAOYSA-N 0.000 description 1
- DJTQTXGNRGBCOD-UHFFFAOYSA-O CC(Cc1c2)CN(C(C(CN(CC3)C(NC)=O)=C3[NH2+]C3CCOCC3)=N)c1cc(C(F)F)c2-c1c[n](C)nc1 Chemical compound CC(Cc1c2)CN(C(C(CN(CC3)C(NC)=O)=C3[NH2+]C3CCOCC3)=N)c1cc(C(F)F)c2-c1c[n](C)nc1 DJTQTXGNRGBCOD-UHFFFAOYSA-O 0.000 description 1
- HAPPNYAXWQZRAX-UHFFFAOYSA-N CC(N(CC1)CC(C(N(CCCc2c3)c2cc(Cl)c3-c2c[n](C)nc2)=N)=C1NC1CCOCC1)=O Chemical compound CC(N(CC1)CC(C(N(CCCc2c3)c2cc(Cl)c3-c2c[n](C)nc2)=N)=C1NC1CCOCC1)=O HAPPNYAXWQZRAX-UHFFFAOYSA-N 0.000 description 1
- PTDAQHCADOZUPK-XKHUQQNRSA-O CC(N(CC1)CC(C(N(CCc2c3)c2ccc3/C(/C=[NH2+])=C/NC)=N)=C1NC1COC1)=O Chemical compound CC(N(CC1)CC(C(N(CCc2c3)c2ccc3/C(/C=[NH2+])=C/NC)=N)=C1NC1COC1)=O PTDAQHCADOZUPK-XKHUQQNRSA-O 0.000 description 1
- NYTUWAJIDVYHTR-UHFFFAOYSA-O CC(N(CC1)CC(C(N2c3cc(-c4c[n](C)nc4)cc(F)c3CC2)=N)=C1[NH2+]C1COCC1)=O Chemical compound CC(N(CC1)CC(C(N2c3cc(-c4c[n](C)nc4)cc(F)c3CC2)=N)=C1[NH2+]C1COCC1)=O NYTUWAJIDVYHTR-UHFFFAOYSA-O 0.000 description 1
- PJUDVGOSAFFXOW-UHFFFAOYSA-N CC(N(CC1)CC(C(Nc(cc2)ccc2-c2cc(C#N)cnc2)=N)=C1NC)=O Chemical compound CC(N(CC1)CC(C(Nc(cc2)ccc2-c2cc(C#N)cnc2)=N)=C1NC)=O PJUDVGOSAFFXOW-UHFFFAOYSA-N 0.000 description 1
- CDQRJTOIKYLWHC-UHFFFAOYSA-N CC(N(CC1)CC(C(Nc2cccc(-c3ccccn3)c2)=N)=C1NCC1CC1)=O Chemical compound CC(N(CC1)CC(C(Nc2cccc(-c3ccccn3)c2)=N)=C1NCC1CC1)=O CDQRJTOIKYLWHC-UHFFFAOYSA-N 0.000 description 1
- TXJYCXYYANUKRH-JFIRURCGSA-O CC(N(CC1)Cc2c1[n](C(CC1)CCC1(F)F)nc2N(CCCc1c2)c1cc(C(F)F)c2/C(/C=[NH2+])=C/NC)=O Chemical compound CC(N(CC1)Cc2c1[n](C(CC1)CCC1(F)F)nc2N(CCCc1c2)c1cc(C(F)F)c2/C(/C=[NH2+])=C/NC)=O TXJYCXYYANUKRH-JFIRURCGSA-O 0.000 description 1
- FOSCIUXFLQMEMH-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C(CC1)CCN1S(C)(=O)=O)nc2N(CCCc1c2)c1cc(C(F)(F)F)c2-c1c[n](C)nc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C(CC1)CCN1S(C)(=O)=O)nc2N(CCCc1c2)c1cc(C(F)(F)F)c2-c1c[n](C)nc1)=O FOSCIUXFLQMEMH-UHFFFAOYSA-N 0.000 description 1
- NOZQJGBVNUQNRB-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C(CCN1)CC1=O)nc2N(CCCc1c2)c1cc(C(F)F)c2-c1c[n](C)nc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C(CCN1)CC1=O)nc2N(CCCc1c2)c1cc(C(F)F)c2-c1c[n](C)nc1)=O NOZQJGBVNUQNRB-UHFFFAOYSA-N 0.000 description 1
- GSHNESMBKPVUKK-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2NC(CC1)=CC=C1c1c[n](CCNC)nc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2NC(CC1)=CC=C1c1c[n](CCNC)nc1)=O GSHNESMBKPVUKK-UHFFFAOYSA-N 0.000 description 1
- UECNFCVMDPPWBS-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)ccc1C#N)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)ccc1C#N)=O UECNFCVMDPPWBS-UHFFFAOYSA-N 0.000 description 1
- HWPRLXIVOJPGBP-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)ccc1C(N(C)C)=O)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)ccc1C(N(C)C)=O)=O HWPRLXIVOJPGBP-UHFFFAOYSA-N 0.000 description 1
- DRXZJLSQJJGIGZ-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)ccc1C(N)=O)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)ccc1C(N)=O)=O DRXZJLSQJJGIGZ-UHFFFAOYSA-N 0.000 description 1
- COVIVMNWGVXQCN-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)ccc1C(N1CCOCC1)=O)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)ccc1C(N1CCOCC1)=O)=O COVIVMNWGVXQCN-UHFFFAOYSA-N 0.000 description 1
- YFDFJEZICRPVLO-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)ccc1Cl)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)ccc1Cl)=O YFDFJEZICRPVLO-UHFFFAOYSA-N 0.000 description 1
- VKTQLUMELSJYIS-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)ccc1F)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)ccc1F)=O VKTQLUMELSJYIS-UHFFFAOYSA-N 0.000 description 1
- BNIJDOOXTWTXBB-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)ccc1OC)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)ccc1OC)=O BNIJDOOXTWTXBB-UHFFFAOYSA-N 0.000 description 1
- UFSZOWMSLVPJKA-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)cnc1C#N)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)cnc1C#N)=O UFSZOWMSLVPJKA-UHFFFAOYSA-N 0.000 description 1
- MHLYKCLCUQKRIA-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)cnc1N)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)cnc1N)=O MHLYKCLCUQKRIA-UHFFFAOYSA-N 0.000 description 1
- VGBJSBQUSBOSFQ-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)cnc1O)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)cnc1O)=O VGBJSBQUSBOSFQ-UHFFFAOYSA-N 0.000 description 1
- SBYNYIDQDRKIQN-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1F)ccc1F)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1F)ccc1F)=O SBYNYIDQDRKIQN-UHFFFAOYSA-N 0.000 description 1
- FSTSATFXXMERTN-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1c(C)ccnc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1c(C)ccnc1)=O FSTSATFXXMERTN-UHFFFAOYSA-N 0.000 description 1
- XKHATCVYWKUWMR-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1c(C)nc(C)cc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1c(C)nc(C)cc1)=O XKHATCVYWKUWMR-UHFFFAOYSA-N 0.000 description 1
- KQOCGYHXPOAIKM-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1c(CCCC2)[n]2nc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1c(CCCC2)[n]2nc1)=O KQOCGYHXPOAIKM-UHFFFAOYSA-N 0.000 description 1
- SSTRQKVGFZOZCS-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1c[n](C)nc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1c[n](C)nc1)=O SSTRQKVGFZOZCS-UHFFFAOYSA-N 0.000 description 1
- APFIMVUTPXXCGR-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1c[n](C)nc1C1CC1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1c[n](C)nc1C1CC1)=O APFIMVUTPXXCGR-UHFFFAOYSA-N 0.000 description 1
- ZXSVBIKPEDHJHL-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1c[n](C2CC2)nc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1c[n](C2CC2)nc1)=O ZXSVBIKPEDHJHL-UHFFFAOYSA-N 0.000 description 1
- ILHQYEASSOOYPH-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cc(C#N)ccc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cc(C#N)ccc1)=O ILHQYEASSOOYPH-UHFFFAOYSA-N 0.000 description 1
- ORAGEWAFIXGRFQ-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cc(C(F)(F)F)ccc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cc(C(F)(F)F)ccc1)=O ORAGEWAFIXGRFQ-UHFFFAOYSA-N 0.000 description 1
- SAKMOVGKLKFYOY-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cc(CO)ccc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cc(CO)ccc1)=O SAKMOVGKLKFYOY-UHFFFAOYSA-N 0.000 description 1
- DIBRXRVMEOFHEB-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cc(F)cc(F)c1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cc(F)cc(F)c1)=O DIBRXRVMEOFHEB-UHFFFAOYSA-N 0.000 description 1
- QIUPBVSHQMFACO-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cc(F)ccc1F)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cc(F)ccc1F)=O QIUPBVSHQMFACO-UHFFFAOYSA-N 0.000 description 1
- KPJLTNBOUVBDAV-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1ccc(C(F)(F)F)cc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1ccc(C(F)(F)F)cc1)=O KPJLTNBOUVBDAV-UHFFFAOYSA-N 0.000 description 1
- CFNPVNSKHBCVKD-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1ccc(C)cc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1ccc(C)cc1)=O CFNPVNSKHBCVKD-UHFFFAOYSA-N 0.000 description 1
- WXCLMMPHFVUIAO-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1ccc(C)nc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1ccc(C)nc1)=O WXCLMMPHFVUIAO-UHFFFAOYSA-N 0.000 description 1
- CQNCIJOYNCPJPT-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1ccc(CO)cc1)O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1ccc(CO)cc1)O CQNCIJOYNCPJPT-UHFFFAOYSA-N 0.000 description 1
- SARDUYMIJOPOTQ-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cccc(Cl)c1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cccc(Cl)c1)=O SARDUYMIJOPOTQ-UHFFFAOYSA-N 0.000 description 1
- ITBMAEGNHCTABP-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cccc(N(C)C)c1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cccc(N(C)C)c1)=O ITBMAEGNHCTABP-UHFFFAOYSA-N 0.000 description 1
- YHFIVAUGWSMFCX-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cccc(NS(C)(=O)=O)c1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cccc(NS(C)(=O)=O)c1)=O YHFIVAUGWSMFCX-UHFFFAOYSA-N 0.000 description 1
- FRIOEGXJPBCNAX-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cccc(OC)c1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cccc(OC)c1)=O FRIOEGXJPBCNAX-UHFFFAOYSA-N 0.000 description 1
- OPGVATQMBWJEIZ-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1ccccc1OC)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1ccccc1OC)=O OPGVATQMBWJEIZ-UHFFFAOYSA-N 0.000 description 1
- UGGSKEWBLNTYIP-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1ccncc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1ccncc1)=O UGGSKEWBLNTYIP-UHFFFAOYSA-N 0.000 description 1
- ZHECXPMTHGPGQQ-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cncc(S=O)c1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cncc(S=O)c1)=O ZHECXPMTHGPGQQ-UHFFFAOYSA-N 0.000 description 1
- OIJFJYQRIPPLEI-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cncnc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cncnc1)=O OIJFJYQRIPPLEI-UHFFFAOYSA-N 0.000 description 1
- STCRPPIWTJYFNV-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1n[n](C)cc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1n[n](C)cc1)=O STCRPPIWTJYFNV-UHFFFAOYSA-N 0.000 description 1
- XJBFFRZIFUFSCO-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCN(C)CC1)nc2N(CCCc1c2)c1cc(C(F)F)c2-c1c[n](C)nc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCN(C)CC1)nc2N(CCCc1c2)c1cc(C(F)F)c2-c1c[n](C)nc1)=O XJBFFRZIFUFSCO-UHFFFAOYSA-N 0.000 description 1
- MVSOEOSCTVFUNY-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCN(CC(F)F)CC1)nc2N(CCCc1c2)c1cc(C(F)F)c2-c1c[n](C)nc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCN(CC(F)F)CC1)nc2N(CCCc1c2)c1cc(C(F)F)c2-c1c[n](C)nc1)=O MVSOEOSCTVFUNY-UHFFFAOYSA-N 0.000 description 1
- RYSZMJJZGAVVTR-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2N(CCCc1c2)c1cc(Cl)c2-c1ccc(C(NC)=O)nc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2N(CCCc1c2)c1cc(Cl)c2-c1ccc(C(NC)=O)nc1)=O RYSZMJJZGAVVTR-UHFFFAOYSA-N 0.000 description 1
- UQBXFDFEKJCZNR-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2N1c(cc(c(-c2c[n](C)nc2)c2)C#N)c2N(C)CC1)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2N1c(cc(c(-c2c[n](C)nc2)c2)C#N)c2N(C)CC1)=O UQBXFDFEKJCZNR-UHFFFAOYSA-N 0.000 description 1
- NRFLQCHTKOFVMD-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1COC1)nc2N(CCc1c2)c1ccc2-c1c[n](C)nc1C(F)(F)F)=O Chemical compound CC(N(CC1)Cc2c1[n](C1COC1)nc2N(CCc1c2)c1ccc2-c1c[n](C)nc1C(F)(F)F)=O NRFLQCHTKOFVMD-UHFFFAOYSA-N 0.000 description 1
- QHKVSIFGMSAWIN-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1COC1)nc2N1c(cccc2)c2OCC1)=O Chemical compound CC(N(CC1)Cc2c1[n](C1COC1)nc2N1c(cccc2)c2OCC1)=O QHKVSIFGMSAWIN-UHFFFAOYSA-N 0.000 description 1
- GUAPUOMXJMGULQ-QKMGMZOJSA-N CC(N(CC1)Cc2c1[n](C1COCC1)nc2N(CC1(CCC1)c1c2)c1ccc2/C(/C=N)=C/NC)=O Chemical compound CC(N(CC1)Cc2c1[n](C1COCC1)nc2N(CC1(CCC1)c1c2)c1ccc2/C(/C=N)=C/NC)=O GUAPUOMXJMGULQ-QKMGMZOJSA-N 0.000 description 1
- NIIYWMZVBGRPFQ-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1COCC1)nc2N(CCc1c2)c1cc(-c1c[n](C)nc1)c2C#N)=O Chemical compound CC(N(CC1)Cc2c1[n](C1COCC1)nc2N(CCc1c2)c1cc(-c1c[n](C)nc1)c2C#N)=O NIIYWMZVBGRPFQ-UHFFFAOYSA-N 0.000 description 1
- ZZJJNIBOIICGMV-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1COCC1)nc2N(CCc1c2)c1ccc2-c1c(C)[n](C)nc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C1COCC1)nc2N(CCc1c2)c1ccc2-c1c(C)[n](C)nc1)=O ZZJJNIBOIICGMV-UHFFFAOYSA-N 0.000 description 1
- VVKXKCAVGFHMJO-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1COCC1)nc2N(CCc1c2)c1ccc2-c1c[n](C)nc1C#N)=O Chemical compound CC(N(CC1)Cc2c1[n](C1COCC1)nc2N(CCc1c2)c1ccc2-c1c[n](C)nc1C#N)=O VVKXKCAVGFHMJO-UHFFFAOYSA-N 0.000 description 1
- VIIVDWHNVKREBX-VYRBHSGPSA-N CC(N(CC1)Cc2c1[n](C1COCC1)nc2N[C@H](C1)C=C(c2c[n](C)nc2)C(F)=C1F)=O Chemical compound CC(N(CC1)Cc2c1[n](C1COCC1)nc2N[C@H](C1)C=C(c2c[n](C)nc2)C(F)=C1F)=O VIIVDWHNVKREBX-VYRBHSGPSA-N 0.000 description 1
- XEIUTMNBFUKUEA-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1COCC1)nc2Nc(cc(cc1)-c2c[n](C)nc2)c1[I]=C)=N Chemical compound CC(N(CC1)Cc2c1[n](C1COCC1)nc2Nc(cc(cc1)-c2c[n](C)nc2)c1[I]=C)=N XEIUTMNBFUKUEA-UHFFFAOYSA-N 0.000 description 1
- ZNIQPKLUCOYTFF-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1COCC1)nc2Nc(cc1)ccc1-c1c[n](C)nc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C1COCC1)nc2Nc(cc1)ccc1-c1c[n](C)nc1)=O ZNIQPKLUCOYTFF-UHFFFAOYSA-N 0.000 description 1
- NJYJBDLOOBAKLR-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1COCC1)nc2Nc(ccc(-c1c[n](C)nc1)c1)c1Cl)=O Chemical compound CC(N(CC1)Cc2c1[n](C1COCC1)nc2Nc(ccc(-c1c[n](C)nc1)c1)c1Cl)=O NJYJBDLOOBAKLR-UHFFFAOYSA-N 0.000 description 1
- PQOUPUVPGGSLQQ-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1COCC1)nc2Nc1ccc(C2C=NN(C)C2C(F)(F)F)cc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C1COCC1)nc2Nc1ccc(C2C=NN(C)C2C(F)(F)F)cc1)=O PQOUPUVPGGSLQQ-UHFFFAOYSA-N 0.000 description 1
- NKXTWOBELGVLPJ-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](CC(CCN1)CC1=O)nc2N(CCCc1c2)c1cc(C(F)F)c2-c1c[n](C)nc1)=O Chemical compound CC(N(CC1)Cc2c1[n](CC(CCN1)CC1=O)nc2N(CCCc1c2)c1cc(C(F)F)c2-c1c[n](C)nc1)=O NKXTWOBELGVLPJ-UHFFFAOYSA-N 0.000 description 1
- MKHZYJVBJCVUJD-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](CC1CC1)nc2Nc1cc(-c2ccncc2)ccc1)=O Chemical compound CC(N(CC1)Cc2c1[n](CC1CC1)nc2Nc1cc(-c2ccncc2)ccc1)=O MKHZYJVBJCVUJD-UHFFFAOYSA-N 0.000 description 1
- WJCOZSIUTNNQCH-ZIGUYKLESA-N CC(N(CC1)Cc2c1[n](CCC(F)(F)F)nc2Nc(cc1)ccc1-c1c[n](CCC(N(CC2)Cc3c2[n](CCC(N)=O)nc3Nc(cc2)ccc2/C(/C=N)=C/NC)=O)nc1)=O Chemical compound CC(N(CC1)Cc2c1[n](CCC(F)(F)F)nc2Nc(cc1)ccc1-c1c[n](CCC(N(CC2)Cc3c2[n](CCC(N)=O)nc3Nc(cc2)ccc2/C(/C=N)=C/NC)=O)nc1)=O WJCOZSIUTNNQCH-ZIGUYKLESA-N 0.000 description 1
- QUDSANXOMKRWBR-FQEVSTJZSA-N CC(N(CC1)Cc2c1[n](CC[C@@H]1COCC1)nc2N(CCc1c2)c1ccc2-c1c(C)[n](C)nc1)=O Chemical compound CC(N(CC1)Cc2c1[n](CC[C@@H]1COCC1)nc2N(CCc1c2)c1ccc2-c1c(C)[n](C)nc1)=O QUDSANXOMKRWBR-FQEVSTJZSA-N 0.000 description 1
- BYSDTPTWZYDBDL-OYRHEFFESA-N CC(N(CC1)Cc2c1[n]([C@H](CC1)CC[C@H]1O)nc2N(CCCc1c2)c1cc(C(F)F)c2-c1c[n](C)nc1)=O Chemical compound CC(N(CC1)Cc2c1[n]([C@H](CC1)CC[C@H]1O)nc2N(CCCc1c2)c1cc(C(F)F)c2-c1c[n](C)nc1)=O BYSDTPTWZYDBDL-OYRHEFFESA-N 0.000 description 1
- JDCXRWQQMMOJEQ-UHFFFAOYSA-N CC(Nc(cc1)ncc1-c(cc1)ccc1Nc1n[n](C)c(CC2)c1CN2C(C)=O)=O Chemical compound CC(Nc(cc1)ncc1-c(cc1)ccc1Nc1n[n](C)c(CC2)c1CN2C(C)=O)=O JDCXRWQQMMOJEQ-UHFFFAOYSA-N 0.000 description 1
- RKBYTUZWJBPSDE-UHFFFAOYSA-N CC(Nc(cc1)ncc1-c(cc1CCC2)c(C(F)F)cc1N2c1n[n](C2CCOCC2)c(CC2)c1CN2C(NC)=O)=O Chemical compound CC(Nc(cc1)ncc1-c(cc1CCC2)c(C(F)F)cc1N2c1n[n](C2CCOCC2)c(CC2)c1CN2C(NC)=O)=O RKBYTUZWJBPSDE-UHFFFAOYSA-N 0.000 description 1
- GCCHDQDWCOCDLK-UHFFFAOYSA-N CC1(c(cc2)ccc2Nc2n[n](C)c(CC3)c2CN3C(C)=O)NNC=C1 Chemical compound CC1(c(cc2)ccc2Nc2n[n](C)c(CC3)c2CN3C(C)=O)NNC=C1 GCCHDQDWCOCDLK-UHFFFAOYSA-N 0.000 description 1
- GSDYNJRRFBBEJS-UHFFFAOYSA-N CC1=CCOC1 Chemical compound CC1=CCOC1 GSDYNJRRFBBEJS-UHFFFAOYSA-N 0.000 description 1
- KAJXBJOCILTJII-UHFFFAOYSA-N CC1c(cc(cc2)-c3c[n](C)nc3)c2N(C)CC1 Chemical compound CC1c(cc(cc2)-c3c[n](C)nc3)c2N(C)CC1 KAJXBJOCILTJII-UHFFFAOYSA-N 0.000 description 1
- OQRQSVFKODEYMA-UHFFFAOYSA-N CCC(CC)N(CCC1)c(cc2C(F)F)c1cc2-c(ccnc1)c1N Chemical compound CCC(CC)N(CCC1)c(cc2C(F)F)c1cc2-c(ccnc1)c1N OQRQSVFKODEYMA-UHFFFAOYSA-N 0.000 description 1
- KHXCSFOBXLYDGJ-UHFFFAOYSA-O CCC1c2cc(C(C=N)=C[NH2+]C)ccc2N(C)C1 Chemical compound CCC1c2cc(C(C=N)=C[NH2+]C)ccc2N(C)C1 KHXCSFOBXLYDGJ-UHFFFAOYSA-O 0.000 description 1
- YHRDDTJESSMWLA-JZQXYNAISA-O CCCC(C)N(CC[C@@H]1C)c2c1cc(/C(/C=[NH2+])=C/NC)c(C#N)c2 Chemical compound CCCC(C)N(CC[C@@H]1C)c2c1cc(/C(/C=[NH2+])=C/NC)c(C#N)c2 YHRDDTJESSMWLA-JZQXYNAISA-O 0.000 description 1
- PFODMDCSNDGMPE-UHFFFAOYSA-N CCCC(CC)N(CC1)c2c1c(Cl)cc(-c1c[n](C)nc1)c2 Chemical compound CCCC(CC)N(CC1)c2c1c(Cl)cc(-c1c[n](C)nc1)c2 PFODMDCSNDGMPE-UHFFFAOYSA-N 0.000 description 1
- FBKNOQMUWJSRPK-UHFFFAOYSA-N CCCC(CC)N(CCC1)c(cc2)c1cc2-c1c[n](C(F)[I]=C)nc1 Chemical compound CCCC(CC)N(CCC1)c(cc2)c1cc2-c1c[n](C(F)[I]=C)nc1 FBKNOQMUWJSRPK-UHFFFAOYSA-N 0.000 description 1
- XOWDMKGWQQKRDZ-UHFFFAOYSA-N CCCC(CC)N(CCC1)c2c1cc(-c1cnc(N(C)C)[s]1)c(C(F)F)c2 Chemical compound CCCC(CC)N(CCC1)c2c1cc(-c1cnc(N(C)C)[s]1)c(C(F)F)c2 XOWDMKGWQQKRDZ-UHFFFAOYSA-N 0.000 description 1
- VUOLINRXKDODNT-UHFFFAOYSA-N CCCCC(CC)N(CC1)c2c1ccc(C#N)c2 Chemical compound CCCCC(CC)N(CC1)c2c1ccc(C#N)c2 VUOLINRXKDODNT-UHFFFAOYSA-N 0.000 description 1
- LYSZWOOLLBURRQ-UHFFFAOYSA-N CCCCC(CCC)N(CCC1)c(cc2)c1cc2-c1c[n](C)c(C)n1 Chemical compound CCCCC(CCC)N(CCC1)c(cc2)c1cc2-c1c[n](C)c(C)n1 LYSZWOOLLBURRQ-UHFFFAOYSA-N 0.000 description 1
- CLBDSPYJYDXQGV-UHFFFAOYSA-N CCCCC(CCC)N(CCC1)c2c1cc(-c1c[n](C)nc1)c(OC(F)(F)F)c2 Chemical compound CCCCC(CCC)N(CCC1)c2c1cc(-c1c[n](C)nc1)c(OC(F)(F)F)c2 CLBDSPYJYDXQGV-UHFFFAOYSA-N 0.000 description 1
- UISBXVKXXGYEOR-UHFFFAOYSA-N CCCCC(CCC)N(CCC1)c2c1cc(-c1c[n](C)nc1)nc2 Chemical compound CCCCC(CCC)N(CCC1)c2c1cc(-c1c[n](C)nc1)nc2 UISBXVKXXGYEOR-UHFFFAOYSA-N 0.000 description 1
- ZAOSJQKDPIERFK-QSVWIEALSA-N CCCCC(CCC)N(CC[C@@H]1CO)c(cc2)c1cc2-c1c[n](C)nc1 Chemical compound CCCCC(CCC)N(CC[C@@H]1CO)c(cc2)c1cc2-c1c[n](C)nc1 ZAOSJQKDPIERFK-QSVWIEALSA-N 0.000 description 1
- AABQTXWBISAECL-UHFFFAOYSA-N CCCCCC(CC)N(CCC1C)c2c1cc(-c1c[n](C)nc1)c(C#N)c2 Chemical compound CCCCCC(CC)N(CCC1C)c2c1cc(-c1c[n](C)nc1)c(C#N)c2 AABQTXWBISAECL-UHFFFAOYSA-N 0.000 description 1
- KAGWUEGUSFLQBK-UHFFFAOYSA-N CCN(C)c(cc1)ccc1-c1c[n](C)nc1 Chemical compound CCN(C)c(cc1)ccc1-c1c[n](C)nc1 KAGWUEGUSFLQBK-UHFFFAOYSA-N 0.000 description 1
- VGZJQQKSDVFGFA-UHFFFAOYSA-N CC[n]1ncc(-c(cc2)ccc2Nc2n[n](C)c(CC3)c2CN3C(C)=O)c1 Chemical compound CC[n]1ncc(-c(cc2)ccc2Nc2n[n](C)c(CC3)c2CN3C(C)=O)c1 VGZJQQKSDVFGFA-UHFFFAOYSA-N 0.000 description 1
- LRLZXUXUQXYOOB-UHFFFAOYSA-N CN(CCC1)c(cc2)c1cc2-c1cc(C#N)cnc1 Chemical compound CN(CCC1)c(cc2)c1cc2-c1cc(C#N)cnc1 LRLZXUXUQXYOOB-UHFFFAOYSA-N 0.000 description 1
- KMXBOEUIAAJSLA-UHFFFAOYSA-N CN(CCC1)c(cc2)c1cc2-c1cncnc1 Chemical compound CN(CCC1)c(cc2)c1cc2-c1cncnc1 KMXBOEUIAAJSLA-UHFFFAOYSA-N 0.000 description 1
- AMDLFSPNCBSFLZ-UHFFFAOYSA-N CN(CCC1)c(cc2C#N)c1cc2-c1ccncn1 Chemical compound CN(CCC1)c(cc2C#N)c1cc2-c1ccncn1 AMDLFSPNCBSFLZ-UHFFFAOYSA-N 0.000 description 1
- MBWCZXOGYULJOO-UHFFFAOYSA-N CN(CCC1)c2c1c(Cl)ccc2 Chemical compound CN(CCC1)c2c1c(Cl)ccc2 MBWCZXOGYULJOO-UHFFFAOYSA-N 0.000 description 1
- UDEULHRWMVNDEF-UHFFFAOYSA-N CN(CCC1)c2c1cc(C1SC=NC1)cc2 Chemical compound CN(CCC1)c2c1cc(C1SC=NC1)cc2 UDEULHRWMVNDEF-UHFFFAOYSA-N 0.000 description 1
- ZCOWMMYJJXWULI-UHFFFAOYSA-N CN(CCCc1c2)c1ccc2-c(cc1)cnc1C#N Chemical compound CN(CCCc1c2)c1ccc2-c(cc1)cnc1C#N ZCOWMMYJJXWULI-UHFFFAOYSA-N 0.000 description 1
- DNIOPDVYJJBBBS-UHFFFAOYSA-N CN(CCc1c2)c1cc(C#N)c2-c1c[n](C)nc1 Chemical compound CN(CCc1c2)c1cc(C#N)c2-c1c[n](C)nc1 DNIOPDVYJJBBBS-UHFFFAOYSA-N 0.000 description 1
- RDKUCKKETDMFBU-UHFFFAOYSA-N CN(c1ccccc1)c(cc1)ccc1-c1c[n](C)nc1 Chemical compound CN(c1ccccc1)c(cc1)ccc1-c1c[n](C)nc1 RDKUCKKETDMFBU-UHFFFAOYSA-N 0.000 description 1
- AKUXPVUGTVAHCD-RMTVOBLGSA-N CN/C=C(\C=N)/c(cc1)cc2c1N(C)C[C@H]2CC#N Chemical compound CN/C=C(\C=N)/c(cc1)cc2c1N(C)C[C@H]2CC#N AKUXPVUGTVAHCD-RMTVOBLGSA-N 0.000 description 1
- YUBKNKQXHGLULJ-PDVFJIAZSA-N CN/C=C(\C=N)/c(cc1)ccc1N(C)c1ccccc1 Chemical compound CN/C=C(\C=N)/c(cc1)ccc1N(C)c1ccccc1 YUBKNKQXHGLULJ-PDVFJIAZSA-N 0.000 description 1
- UTRSDTNSYNOFHK-BXBRPASWSA-O CN/C=C(\C=[NH2+])/c(cc1)cc(C2)c1N(C)CC2C1CC1 Chemical compound CN/C=C(\C=[NH2+])/c(cc1)cc(C2)c1N(C)CC2C1CC1 UTRSDTNSYNOFHK-BXBRPASWSA-O 0.000 description 1
- XSWFYGFHEHETNV-VVJXHRSYSA-O CN/C=C(\C=[NH2+])/c(cc1)cc2c1N(C)CC(CC(F)F)C2 Chemical compound CN/C=C(\C=[NH2+])/c(cc1)cc2c1N(C)CC(CC(F)F)C2 XSWFYGFHEHETNV-VVJXHRSYSA-O 0.000 description 1
- PYTBFFZXPKUFHY-FMBUXQRRSA-O CN/C=C(\C=[NH2+])/c1ccc2N(C)CC(CO)Cc2c1 Chemical compound CN/C=C(\C=[NH2+])/c1ccc2N(C)CC(CO)Cc2c1 PYTBFFZXPKUFHY-FMBUXQRRSA-O 0.000 description 1
- QWVPFQJBXPZUSK-UHFFFAOYSA-N CNC(N(CC1)CC(C(N(CCC2)c3c2cc(-c2c[n](C)nc2)c(C(F)F)c3)=N)=C1NC(CC1)CCC1OC)=O Chemical compound CNC(N(CC1)CC(C(N(CCC2)c3c2cc(-c2c[n](C)nc2)c(C(F)F)c3)=N)=C1NC(CC1)CCC1OC)=O QWVPFQJBXPZUSK-UHFFFAOYSA-N 0.000 description 1
- WISNGFXEEMWAHJ-UHFFFAOYSA-N CNC(N(CC1)CC(C(N(CCC2)c3c2cc(-c2c[n](C)nc2)c(C(F)F)c3)=N)=C1Nc1cccnc1)=O Chemical compound CNC(N(CC1)CC(C(N(CCC2)c3c2cc(-c2c[n](C)nc2)c(C(F)F)c3)=N)=C1Nc1cccnc1)=O WISNGFXEEMWAHJ-UHFFFAOYSA-N 0.000 description 1
- HXEBYFYBKCPGQZ-UHFFFAOYSA-O CNC(N(CC1)CC(C(N(CCCc2c3)c2cc(Cl)c3-c2c[n](C)nc2)=N)=C1[NH2+]C1CCOCC1)=O Chemical compound CNC(N(CC1)CC(C(N(CCCc2c3)c2cc(Cl)c3-c2c[n](C)nc2)=N)=C1[NH2+]C1CCOCC1)=O HXEBYFYBKCPGQZ-UHFFFAOYSA-O 0.000 description 1
- NHPSOTYCPZNXSW-UHFFFAOYSA-O CNC(N(CC1)CC(C(N2C3C=C(C(F)(F)F)C(c4c[n](C)nc4)=CC3CCC2)=N)=C1[NH2+]C1CCOCC1)=O Chemical compound CNC(N(CC1)CC(C(N2C3C=C(C(F)(F)F)C(c4c[n](C)nc4)=CC3CCC2)=N)=C1[NH2+]C1CCOCC1)=O NHPSOTYCPZNXSW-UHFFFAOYSA-O 0.000 description 1
- OLCHZCYSJRUSRX-UHFFFAOYSA-N CNC(N(CC1)Cc2c1[n](-c1ccccc1)nc2N(CCCc1c2)c1cc(C(F)F)c2-c1c[n](C)nc1)=O Chemical compound CNC(N(CC1)Cc2c1[n](-c1ccccc1)nc2N(CCCc1c2)c1cc(C(F)F)c2-c1c[n](C)nc1)=O OLCHZCYSJRUSRX-UHFFFAOYSA-N 0.000 description 1
- NKBOSLMTOJMTLZ-UHFFFAOYSA-N CNC(N(CC1)Cc2c1[n](-c1ccncc1)nc2N(CCCc1c2)c1cc(C(F)F)c2-c1c[n](C)nc1)=O Chemical compound CNC(N(CC1)Cc2c1[n](-c1ccncc1)nc2N(CCCc1c2)c1cc(C(F)F)c2-c1c[n](C)nc1)=O NKBOSLMTOJMTLZ-UHFFFAOYSA-N 0.000 description 1
- DCYODTYUBWATHC-UHFFFAOYSA-N CNC(N(CC1)Cc2c1[n](C1CCCCC1)nc2N(CCC1)c2c1cc(-c1c[n](C)nc1)c(C(F)F)c2)=O Chemical compound CNC(N(CC1)Cc2c1[n](C1CCCCC1)nc2N(CCC1)c2c1cc(-c1c[n](C)nc1)c(C(F)F)c2)=O DCYODTYUBWATHC-UHFFFAOYSA-N 0.000 description 1
- BLKIJAZMPMNLOV-UHFFFAOYSA-N CNC(N(CC1)Cc2c1[n](C1CCOCC1)nc2N(CCCc1c2)c1cc(C1CC1)c2-c1c[n](C)nc1)=O Chemical compound CNC(N(CC1)Cc2c1[n](C1CCOCC1)nc2N(CCCc1c2)c1cc(C1CC1)c2-c1c[n](C)nc1)=O BLKIJAZMPMNLOV-UHFFFAOYSA-N 0.000 description 1
- JQDHNNIGFYFJHU-UHFFFAOYSA-N CNC(N(CC1)Cc2c1[n](C1CCOCC1)nc2N(CCCc1c2)c1cc(C=C)c2-c1c[n](C)nc1)=O Chemical compound CNC(N(CC1)Cc2c1[n](C1CCOCC1)nc2N(CCCc1c2)c1cc(C=C)c2-c1c[n](C)nc1)=O JQDHNNIGFYFJHU-UHFFFAOYSA-N 0.000 description 1
- VDEXIQHMSLVIIG-UHFFFAOYSA-N CNC(N(CC1)Cc2c1[n](C1CCOCC1)nc2N(CCCc1c2)c1cc(S(C)(=O)=O)c2-c1c[n](C)nc1)=O Chemical compound CNC(N(CC1)Cc2c1[n](C1CCOCC1)nc2N(CCCc1c2)c1cc(S(C)(=O)=O)c2-c1c[n](C)nc1)=O VDEXIQHMSLVIIG-UHFFFAOYSA-N 0.000 description 1
- GESFMFCLSDLZCV-UHFFFAOYSA-N CNC(N(CC1)Cc2c1[n](C1CCOCC1)nc2N1c(cc(c(-c2c[n](C)nc2)c2)C#N)c2N(C)CC1)=O Chemical compound CNC(N(CC1)Cc2c1[n](C1CCOCC1)nc2N1c(cc(c(-c2c[n](C)nc2)c2)C#N)c2N(C)CC1)=O GESFMFCLSDLZCV-UHFFFAOYSA-N 0.000 description 1
- QIVDEDWWJMXDJB-MXVIHJGJSA-N CNC(N(CC1)Cc2c1[n]([C@H](CC1)CC[C@@H]1N)nc2N(CCC1)c2c1cc(-c1c[n](C)nc1)c(C(F)F)c2)=O Chemical compound CNC(N(CC1)Cc2c1[n]([C@H](CC1)CC[C@@H]1N)nc2N(CCC1)c2c1cc(-c1c[n](C)nc1)c(C(F)F)c2)=O QIVDEDWWJMXDJB-MXVIHJGJSA-N 0.000 description 1
- NCMLBFFUDRTDQF-NSHDSACASA-N C[C@@H](C1)CN(C)c2c1cc(-c1c[n](C)nc1)c(C#N)c2 Chemical compound C[C@@H](C1)CN(C)c2c1cc(-c1c[n](C)nc1)c(C#N)c2 NCMLBFFUDRTDQF-NSHDSACASA-N 0.000 description 1
- YWKGZWFAUXSDJY-OXJNMPFZSA-N C[C@@H](C1)c2cc(-c3c[n](C)nc3)ccc2N1c1n[n]([C@H]2COCC2)c(CC2)c1CN2C(C)=O Chemical compound C[C@@H](C1)c2cc(-c3c[n](C)nc3)ccc2N1c1n[n]([C@H]2COCC2)c(CC2)c1CN2C(C)=O YWKGZWFAUXSDJY-OXJNMPFZSA-N 0.000 description 1
- KTZSWHMPAOVIBK-PROIXAHCSA-N C[C@@H](C1)c2cc(/C(/C=N)=C/NC)ccc2N1c1n[n]([C@@H]2COCC2)c(CC2)c1CN2C(C)=O Chemical compound C[C@@H](C1)c2cc(/C(/C=N)=C/NC)ccc2N1c1n[n]([C@@H]2COCC2)c(CC2)c1CN2C(C)=O KTZSWHMPAOVIBK-PROIXAHCSA-N 0.000 description 1
- JYXKEWDWKKISID-INIZCTEOSA-N C[C@@H](C1CC1)[n](c(CC1)c2CN1C(NC)=O)nc2N(CCC1)c2c1cc(-c1c[n](C)nc1)c(C(F)F)c2 Chemical compound C[C@@H](C1CC1)[n](c(CC1)c2CN1C(NC)=O)nc2N(CCC1)c2c1cc(-c1c[n](C)nc1)c(C(F)F)c2 JYXKEWDWKKISID-INIZCTEOSA-N 0.000 description 1
- DJTQTXGNRGBCOD-KRWDZBQOSA-N C[C@@H](Cc1c2)CN(C(C(CN(CC3)C(NC)=O)=C3NC3CCOCC3)=N)c1cc(C(F)F)c2-c1c[n](C)nc1 Chemical compound C[C@@H](Cc1c2)CN(C(C(CN(CC3)C(NC)=O)=C3NC3CCOCC3)=N)c1cc(C(F)F)c2-c1c[n](C)nc1 DJTQTXGNRGBCOD-KRWDZBQOSA-N 0.000 description 1
- KAJXBJOCILTJII-NSHDSACASA-N C[C@@H]1c(cc(cc2)-c3c[n](C)nc3)c2N(C)CC1 Chemical compound C[C@@H]1c(cc(cc2)-c3c[n](C)nc3)c2N(C)CC1 KAJXBJOCILTJII-NSHDSACASA-N 0.000 description 1
- MLRPMBYWAALRFR-GOSISDBHSA-N C[C@H](C1)N(C)c(cc(-c2c[n](C)nc2)c(NC)c2)c2N1c1n[n](C2CCOCC2)c(CC2)c1CN2C(C)=O Chemical compound C[C@H](C1)N(C)c(cc(-c2c[n](C)nc2)c(NC)c2)c2N1c1n[n](C2CCOCC2)c(CC2)c1CN2C(C)=O MLRPMBYWAALRFR-GOSISDBHSA-N 0.000 description 1
- KTZSWHMPAOVIBK-OXODIXQHSA-N C[C@H](C1)c(cc(cc2)/C(/C=N)=C/NC)c2N1c1n[n]([C@@H]2COCC2)c(CC2)c1CN2C(C)=O Chemical compound C[C@H](C1)c(cc(cc2)/C(/C=N)=C/NC)c2N1c1n[n]([C@@H]2COCC2)c(CC2)c1CN2C(C)=O KTZSWHMPAOVIBK-OXODIXQHSA-N 0.000 description 1
- YWKGZWFAUXSDJY-OXQOHEQNSA-N C[C@H](C1)c2cc(-c3c[n](C)nc3)ccc2N1c1n[n]([C@H]2COCC2)c(CC2)c1CN2C(C)=O Chemical compound C[C@H](C1)c2cc(-c3c[n](C)nc3)ccc2N1c1n[n]([C@H]2COCC2)c(CC2)c1CN2C(C)=O YWKGZWFAUXSDJY-OXQOHEQNSA-N 0.000 description 1
- YBDQLHBVNXARAU-ZCFIWIBFSA-N C[C@H]1OCCCC1 Chemical compound C[C@H]1OCCCC1 YBDQLHBVNXARAU-ZCFIWIBFSA-N 0.000 description 1
- JGXJVICBEGNSIF-SJQKCGLASA-O C[C@H]1c(cc(cc2)/C(/C=[NH2+])=C/NC)c2N(C)CC1 Chemical compound C[C@H]1c(cc(cc2)/C(/C=[NH2+])=C/NC)c2N(C)CC1 JGXJVICBEGNSIF-SJQKCGLASA-O 0.000 description 1
- FYMVTDZRRWWRBV-UHFFFAOYSA-N C[N+]1(CCC2(CC2)CC1)[O-] Chemical compound C[N+]1(CCC2(CC2)CC1)[O-] FYMVTDZRRWWRBV-UHFFFAOYSA-N 0.000 description 1
- HSZOMYJQTCPQFF-UHFFFAOYSA-N C[n](cc1)nc1-c(cc1)cc2c1N(C)CCC2 Chemical compound C[n](cc1)nc1-c(cc1)cc2c1N(C)CCC2 HSZOMYJQTCPQFF-UHFFFAOYSA-N 0.000 description 1
- HYRKQAWMRNJTNV-UHFFFAOYSA-N C[n]1nc(C(F)F)c(-c(cc2)cc3c2N(C)CCC3)c1 Chemical compound C[n]1nc(C(F)F)c(-c(cc2)cc3c2N(C)CCC3)c1 HYRKQAWMRNJTNV-UHFFFAOYSA-N 0.000 description 1
- YMTQPRIAAJEJJH-UHFFFAOYSA-N C[n]1ncc(-c(c(OC)c2)cc3c2N(C)CCC3)c1 Chemical compound C[n]1ncc(-c(c(OC)c2)cc3c2N(C)CCC3)c1 YMTQPRIAAJEJJH-UHFFFAOYSA-N 0.000 description 1
- QVTYVXATVZRULO-UHFFFAOYSA-N C[n]1ncc(-c(cc(CCCN2C)c2c2)c2C#N)c1 Chemical compound C[n]1ncc(-c(cc(CCCN2C)c2c2)c2C#N)c1 QVTYVXATVZRULO-UHFFFAOYSA-N 0.000 description 1
- VTYXZXKTLLVOSE-UHFFFAOYSA-N C[n]1ncc(-c(cc2)cc(C3)c2N(C)CC3c2ccccc2)c1 Chemical compound C[n]1ncc(-c(cc2)cc(C3)c2N(C)CC3c2ccccc2)c1 VTYXZXKTLLVOSE-UHFFFAOYSA-N 0.000 description 1
- CDPTWLTVTCIUCU-UHFFFAOYSA-N C[n]1ncc(-c(cc2)cc3c2N(C)CC(COC)C3)c1 Chemical compound C[n]1ncc(-c(cc2)cc3c2N(C)CC(COC)C3)c1 CDPTWLTVTCIUCU-UHFFFAOYSA-N 0.000 description 1
- PMARIRPNODGTDV-UHFFFAOYSA-N C[n]1ncc(-c(cc2)cc3c2N(C)CCC3CO)c1 Chemical compound C[n]1ncc(-c(cc2)cc3c2N(C)CCC3CO)c1 PMARIRPNODGTDV-UHFFFAOYSA-N 0.000 description 1
- TVRLTDQPAUCUOE-UHFFFAOYSA-N C[n]1ncc(-c(cc2)cc3c2N(C)CCN3)c1 Chemical compound C[n]1ncc(-c(cc2)cc3c2N(C)CCN3)c1 TVRLTDQPAUCUOE-UHFFFAOYSA-N 0.000 description 1
- QVFCQBWCSZMULB-UHFFFAOYSA-N Cc(cc(C(NC)=O)nc1)c1-c(c(C#N)c1)cc2c1N(C)CCC2 Chemical compound Cc(cc(C(NC)=O)nc1)c1-c(c(C#N)c1)cc2c1N(C)CCC2 QVFCQBWCSZMULB-UHFFFAOYSA-N 0.000 description 1
- AFZXPYWOBUSUHJ-UHFFFAOYSA-N Cc(cc(c(CCC1)c2)N1c1n[n](C3CCOCC3)c(CC3)c1CN3C(NC)=O)c2-c1c[n](C)nc1 Chemical compound Cc(cc(c(CCC1)c2)N1c1n[n](C3CCOCC3)c(CC3)c1CN3C(NC)=O)c2-c1c[n](C)nc1 AFZXPYWOBUSUHJ-UHFFFAOYSA-N 0.000 description 1
- KFVPUFFWZHPGKR-UHFFFAOYSA-N Cc1c(-c2c(C(F)F)cc3N(C)CCCc3c2)[s]c(C)n1 Chemical compound Cc1c(-c2c(C(F)F)cc3N(C)CCCc3c2)[s]c(C)n1 KFVPUFFWZHPGKR-UHFFFAOYSA-N 0.000 description 1
- IXRUIAJQIUHYEB-UHFFFAOYSA-N Cc1cc(-c(c(C#N)c2)cc3c2N(C)CCC3)cnc1C(NC)=O Chemical compound Cc1cc(-c(c(C#N)c2)cc3c2N(C)CCC3)cnc1C(NC)=O IXRUIAJQIUHYEB-UHFFFAOYSA-N 0.000 description 1
- TWJOIFSCBRNBBE-UHFFFAOYSA-N Cc1cc(-c(c(C(F)F)c2)cc3c2N(C)CCC3)n[n]1C Chemical compound Cc1cc(-c(c(C(F)F)c2)cc3c2N(C)CCC3)n[n]1C TWJOIFSCBRNBBE-UHFFFAOYSA-N 0.000 description 1
- DLJJEYCPQOXWES-UHFFFAOYSA-N Cc1cc(-c(cc(CCCN2C)c2c2)c2C#N)ncc1 Chemical compound Cc1cc(-c(cc(CCCN2C)c2c2)c2C#N)ncc1 DLJJEYCPQOXWES-UHFFFAOYSA-N 0.000 description 1
- CILODPACWHFOCO-UHFFFAOYSA-N Cc1cc(-c2c[n](C)nc2)cc(I)c1 Chemical compound Cc1cc(-c2c[n](C)nc2)cc(I)c1 CILODPACWHFOCO-UHFFFAOYSA-N 0.000 description 1
- LXTLBLFQNPYOTF-UHFFFAOYSA-N Cc1cc(N(C)CCC2)c2cc1-c1c[n](C)nc1 Chemical compound Cc1cc(N(C)CCC2)c2cc1-c1c[n](C)nc1 LXTLBLFQNPYOTF-UHFFFAOYSA-N 0.000 description 1
- ILGIZHJZQMOHKT-UHFFFAOYSA-N Cc1ccc(-c(c(C#N)c2)cc3c2N(C)CCC3)nc1 Chemical compound Cc1ccc(-c(c(C#N)c2)cc3c2N(C)CCC3)nc1 ILGIZHJZQMOHKT-UHFFFAOYSA-N 0.000 description 1
- WBFBGAIIYFQWBH-UHFFFAOYSA-N Cc1cnccc1-c(c(C#N)c1)cc2c1N(C)CCC2 Chemical compound Cc1cnccc1-c(c(C#N)c1)cc2c1N(C)CCC2 WBFBGAIIYFQWBH-UHFFFAOYSA-N 0.000 description 1
- CMVMLEAWGSGYEC-UHFFFAOYSA-N Cc1n[n](C)cc1-c(c(C#N)c1)cc2c1N(C)CCC2 Chemical compound Cc1n[n](C)cc1-c(c(C#N)c1)cc2c1N(C)CCC2 CMVMLEAWGSGYEC-UHFFFAOYSA-N 0.000 description 1
- MINYWMSCUCJKMH-UHFFFAOYSA-N Cc1nc(-c(c(C#N)c2)cc3c2N(C)CCC3)ccc1 Chemical compound Cc1nc(-c(c(C#N)c2)cc3c2N(C)CCC3)ccc1 MINYWMSCUCJKMH-UHFFFAOYSA-N 0.000 description 1
- FWBGXVWXBCQJRM-UHFFFAOYSA-N Cc1ncc(-c(c(C(F)F)c2)cc3c2N(C)CCC3)[s]1 Chemical compound Cc1ncc(-c(c(C(F)F)c2)cc3c2N(C)CCC3)[s]1 FWBGXVWXBCQJRM-UHFFFAOYSA-N 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014092380 | 2014-11-27 | ||
| CNPCT/CN2014/092380 | 2014-11-27 | ||
| CNPCT/CN2015/092965 | 2015-10-27 | ||
| CN2015092965 | 2015-10-27 | ||
| PCT/US2015/062794 WO2016086200A1 (en) | 2014-11-27 | 2015-11-25 | 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537100A JP2017537100A (ja) | 2017-12-14 |
| JP2017537100A5 true JP2017537100A5 (enExample) | 2019-01-10 |
| JP6771464B2 JP6771464B2 (ja) | 2020-10-21 |
Family
ID=55024234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017528520A Active JP6771464B2 (ja) | 2014-11-27 | 2015-11-25 | Ｃｂｐおよび／またはｅｐ３００インヒビターとしての、４，５，６，７−テトラヒドロ−１ｈ−ピラゾロ［４，３−ｃ］ピリジン−３−アミン化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US9763922B2 (enExample) |
| EP (2) | EP3224258B1 (enExample) |
| JP (1) | JP6771464B2 (enExample) |
| CN (1) | CN107531690B (enExample) |
| WO (1) | WO2016086200A1 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016077375A1 (en) | 2014-11-10 | 2016-05-19 | Genentech, Inc. | Bromodomain inhibitors and uses thereof |
| MA40940A (fr) * | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| MA40943A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| RU2745999C1 (ru) * | 2014-12-05 | 2021-04-05 | Х. Ли Моффитт Кэнсер Сентер Энд Рисёч Инститьют, Инк. | Ингибитор бромодомена в качестве адъюванта в противоопухолевой иммунотерапии |
| CN107531692B (zh) | 2015-01-29 | 2020-12-25 | 基因泰克公司 | 治疗化合物及其用途 |
| AR104259A1 (es) * | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
| JP7160688B2 (ja) * | 2016-05-24 | 2022-10-25 | ジェネンテック， インコーポレイテッド | Ｃｂｐ／ｅｐ３００の複素環式インヒビターおよびがんの処置におけるそれらの使用 |
| EP3464286B1 (en) * | 2016-05-24 | 2021-08-18 | Genentech, Inc. | Pyrazolopyridine derivatives for the treatment of cancer |
| CA3031525A1 (en) | 2016-07-25 | 2018-02-01 | Epizyme, Inc. | Crebbp related cancer therapy |
| GB201617630D0 (en) * | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201617627D0 (en) * | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| TW201906838A (zh) | 2017-06-21 | 2019-02-16 | 日商第一三共股份有限公司 | Ｅｐ３００／ｃｒｅｂｂｐ抑制劑 |
| TWI846350B (zh) * | 2017-09-15 | 2024-06-21 | 美商佛瑪治療公司 | 作為ＣＢＰ／ｐ３００抑制劑之四氫－咪唑並喹啉化合物 |
| EA202091114A1 (ru) | 2017-11-02 | 2020-07-24 | Айкурис Гмбх Унд Ко. Кг | Новые высокоактивные пиразолопиперидин-замещенные индол-2-карбоксамиды, активные против вируса гепатита в (hbv) |
| AU2019245403B2 (en) * | 2018-03-29 | 2025-02-06 | Board Of Regents, The University Of Texas System | Imidazopiperazine inhibitors of transcription activating proteins |
| US10899769B2 (en) | 2018-04-06 | 2021-01-26 | Board Of Regents, The University Of Texas System | Imidazopiperazinone inhibitors of transcription activating proteins |
| GB201806320D0 (en) * | 2018-04-18 | 2018-05-30 | Cellcentric Ltd | Process |
| GB201809295D0 (en) | 2018-06-06 | 2018-07-25 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
| EP3587418B1 (en) * | 2018-06-29 | 2021-09-01 | Forma Therapeutics, Inc. | Inhibitors of creb binding protein (cbp) |
| KR102805503B1 (ko) * | 2018-06-29 | 2025-05-09 | 포르마 세라퓨틱스 인크. | Creb 결합 단백질(cbp)의 저해 |
| CN109187832B (zh) * | 2018-09-30 | 2021-07-30 | 华润三九医药股份有限公司 | Lc-ms/ms测定去氧肾上腺素浓度的方法及样品的前处理方法 |
| GB201818750D0 (en) | 2018-11-16 | 2019-01-02 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
| CN111320621B (zh) * | 2018-12-14 | 2022-10-04 | 中国科学院广州生物医药与健康研究院 | 一种吲嗪类化合物及其制备方法和应用 |
| WO2020173440A1 (en) * | 2019-02-27 | 2020-09-03 | Cullgen (Shanghai), Inc. | Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of use |
| CA3131383A1 (en) * | 2019-02-27 | 2020-09-03 | Constellation Pharmaceuticals, Inc. | P300/cbp hat inhibitors and methods for their use |
| WO2020190791A1 (en) * | 2019-03-15 | 2020-09-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (creb) |
| EP3938365A4 (en) * | 2019-03-15 | 2023-01-25 | Forma Therapeutics, Inc. | COMPOSITIONS AND METHODS OF TREATMENT OF ANDROGEN RECEPTOR POSITIVE FORMS OF CANCER |
| JP2022535743A (ja) * | 2019-05-29 | 2022-08-10 | アイエフエム デュー インコーポレイテッド | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
| CN110170052B (zh) * | 2019-06-21 | 2020-07-10 | 复旦大学 | Cbp-p300抑制剂在肠道损伤疾病中的应用 |
| TW202120095A (zh) | 2019-08-05 | 2021-06-01 | 美商美國禮來大藥廠 | 7,8-二氫-4H-吡唑并[4,3-c]氮呯-6-酮化合物 |
| JP2022549506A (ja) | 2019-09-27 | 2022-11-25 | ディスク・メディシン・インコーポレイテッド | 骨髄線維症および関連状態を処置するための方法 |
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| AU2021259814B2 (en) | 2020-04-25 | 2023-09-28 | Pharmablock Sciences (Nanjing), Inc. | CBP/EP300 inhibitor and use thereof |
| AU2021270458A1 (en) | 2020-05-13 | 2022-11-10 | AbbVie Deutschland GmbH & Co. KG | Anti-hemojuvelin (HJV) antibodies for treating myelofibrosis |
| CN116507333B (zh) * | 2020-08-27 | 2025-05-09 | 上海睿跃生物科技有限公司 | 环amp反应元件结合蛋白(cbp)和/或300kda腺病毒e1a结合蛋白(p300)降解化合物和使用方法 |
| US11801243B2 (en) | 2020-09-23 | 2023-10-31 | Forma Therapeutics, Inc. | Bromodomain inhibitors for androgen receptor-driven cancers |
| US11795168B2 (en) | 2020-09-23 | 2023-10-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP) |
| EP4221709A4 (en) * | 2020-10-02 | 2024-10-02 | Board of Regents, The University of Texas System | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION-ACTIVATING PROTEINS |
| EP4221708A4 (en) * | 2020-10-02 | 2024-11-06 | Board of Regents, The University of Texas System | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION-ACTIVATING PROTEINS |
| JPWO2022138944A1 (enExample) * | 2020-12-25 | 2022-06-30 | ||
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| CN115340529A (zh) * | 2021-05-14 | 2022-11-15 | 武汉朗来科技发展有限公司 | 一种rock抑制剂的酸加成盐及盐的晶型、组合物和药物用途 |
| WO2023083286A1 (en) | 2021-11-12 | 2023-05-19 | Insilico Medicine Ip Limited | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
| US20240109868A1 (en) * | 2022-08-29 | 2024-04-04 | Miracure Biotechnology Limited | Ep300/cbp modulator, preparation method therefor and use thereof |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| WO2025001864A1 (en) * | 2023-06-30 | 2025-01-02 | Beijing Double-Crane Runchuang Technology Co., Ltd. | Fascin inhibitors |
| CN117069956B (zh) * | 2023-08-22 | 2025-04-08 | 南京科技职业学院 | 一种具有一维超分子结构的手性膦镍(ii)配合物及其制备方法和应用 |
| WO2025111184A1 (en) | 2023-11-21 | 2025-05-30 | Fmc Corporation | Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides |
| WO2025108411A1 (zh) * | 2023-11-24 | 2025-05-30 | 北京沐华生物科技有限责任公司 | 一种ep300/cbp调节剂及其制备方法和用途 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| EP0491007B1 (en) | 1989-09-08 | 1996-03-13 | The Johns Hopkins University | Structural alterations of the egf receptor gene in human gliomas |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| EP0659439B1 (en) | 1993-12-24 | 2001-10-24 | MERCK PATENT GmbH | Immunoconjugates |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| EP0772609B1 (en) | 1994-07-21 | 1999-02-24 | Akzo Nobel N.V. | Cyclic ketone peroxide formulations |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| DE122005000053I2 (de) | 1995-03-30 | 2008-01-17 | Pfizer Prod Inc | Chinazolinderivate |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
| PT836605E (pt) | 1995-07-06 | 2002-07-31 | Novartis Ag | Pirrolopirimidinas e processos para a sua preparacao |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| US6344459B1 (en) | 1996-04-12 | 2002-02-05 | Warner-Lambert Company | Irreversible inhibitors of tyrosine kinases |
| ES2186908T3 (es) | 1996-07-13 | 2003-05-16 | Glaxo Group Ltd | Compuestos heterociciclos condensados como inhibidores de pproteina-tirosina-quinasas. |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| AU7165698A (en) | 1997-05-06 | 1998-11-27 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| HUP0004286A3 (en) | 1997-11-06 | 2002-01-28 | American Cyanamid Co Madison | Use of quinazoline derivatives for producing pharmaceutical compositions for treating colonic polyps |
| HUP0104211A3 (en) | 1998-11-19 | 2003-01-28 | Warner Lambert Co | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases and pharmaceutical composition containing it |
| JP2005537290A (ja) | 2002-07-25 | 2005-12-08 | ファルマシア・イタリア・エス・ピー・エー | キナーゼ阻害剤として活性なビシクロピラゾール類、その製造方法、およびそれを含有する薬学的組成物 |
| EP1526852A1 (en) | 2002-07-25 | 2005-05-04 | Pharmacia Italia S.p.A. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| EP1608364A1 (en) | 2003-03-11 | 2005-12-28 | Pharmacia Italia S.p.A. | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| CA2970873C (en) | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| JP5219150B2 (ja) | 2005-12-12 | 2013-06-26 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | キナーゼ阻害薬として活性な置換ピラゾロ［４，３−ｃ］ピリジン誘導体 |
| WO2007099166A1 (en) | 2006-03-03 | 2007-09-07 | Nerviano Medical Sciences S.R.L. | Pyrazolo-pyridine derivatives active as kinase inhibitors |
| CN101910182B (zh) * | 2007-12-28 | 2013-07-17 | 田边三菱制药株式会社 | 抗癌剂 |
| BRPI0907718A2 (pt) | 2008-02-11 | 2017-06-13 | Curetech Ltd | método para tratar um tumor, método para melhorar a tolerabilidade a pelo menos um agente quimiterápico, método para aumentar a sobrevida de um indivíduo que tem um tumor, método para reduzir ou prevenir recidiva tumoral, uso de um anticorpo monoclonal humanizado ou seu fragmento e anticorpo monoclonal humanizado ou seu fragmento |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| AR071780A1 (es) | 2008-05-15 | 2010-07-14 | Nerviano Medical Sciences Srl | Derivados de carbamoilo de carbonilamino-pirazoles biciclicos como profarmacos |
| EA201170375A1 (ru) | 2008-08-25 | 2012-03-30 | Эмплиммьюн, Инк. | Антагонисты pd-1 и способы их применения |
| FI4209510T3 (fi) | 2008-12-09 | 2024-03-22 | Hoffmann La Roche | Anti-PD-L1-vasta-aineita ja niiden käyttö T-solutoiminnan tehostamiseksi |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| CN101812063B (zh) | 2010-03-18 | 2012-04-25 | 中国医学科学院医药生物技术研究所 | α-萘磺酰胺基五元杂环类化合物及其抑瘤活性 |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| WO2013148114A1 (en) * | 2012-03-30 | 2013-10-03 | University Of Florida Research Foundation, Inc. | P300/cbp inhibitors and methods of use |
| WO2014138727A1 (en) * | 2013-03-08 | 2014-09-12 | Board Of Regents, The University Of Texas System | Suppression of malignant mesothelioma by overexpression or stimulation of endothelial protein c receptors (epcr) |
-
2015
- 2015-11-25 CN CN201580074597.7A patent/CN107531690B/zh active Active
- 2015-11-25 WO PCT/US2015/062794 patent/WO2016086200A1/en not_active Ceased
- 2015-11-25 JP JP2017528520A patent/JP6771464B2/ja active Active
- 2015-11-25 EP EP15816578.7A patent/EP3224258B1/en active Active
- 2015-11-25 EP EP19191423.3A patent/EP3632915A1/en not_active Withdrawn
- 2015-11-25 US US14/952,821 patent/US9763922B2/en active Active
-
2017
- 2017-08-02 US US15/667,227 patent/US20170333406A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537100A5 (enExample) | ||
| JP2017530176A5 (enExample) | ||
| JP2019516757A5 (enExample) | ||
| JP2019516759A5 (enExample) | ||
| JP2017526696A5 (enExample) | ||
| JP2017533250A5 (enExample) | ||
| Isanbor et al. | Fluorine in medicinal chemistry: A review of anti-cancer agents | |
| JP2017533249A5 (enExample) | ||
| JP2017533248A5 (enExample) | ||
| JP2017525740A5 (enExample) | ||
| JP6835472B2 (ja) | 癌の処置のための組成物 | |
| JP2018501287A5 (enExample) | ||
| JP2018510851A5 (enExample) | ||
| JP6847120B2 (ja) | チェックポイントインヒビターを強化するためのグルココルチコイドレセプターモジュレーターの使用 | |
| CN102985403B (zh) | 具有抗雄激素性质的新型芳基酰胺衍生物 | |
| JP2016529312A5 (enExample) | ||
| ZA200307665B (en) | Combination comprising N-{5-[4-(4-methyl-piperazinomethyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and a chemotherapeutic agent. | |
| JP2018507191A5 (enExample) | ||
| KR20140025433A (ko) | Ａｋｔ 억제제 화합물 및 베무라페닙의 조합물, 및 사용 방법 | |
| JP2014506601A5 (enExample) | ||
| RU2020131507A (ru) | Имидазопиперазиновые ингибиторы белков-активаторов транскрипции | |
| JP2019529444A5 (enExample) | ||
| IL191803A (en) | Substances that bind intracranial receptors | |
| Anwar Omar et al. | A novel cyclobutane-derived thiazole–thiourea hybrid with a potency against COVID-19 and tick-borne encephalitis: synthesis, characterization, and computational analysis | |
| JP2011521938A5 (enExample) |